UROLUCOSIL TREATMENT OF “B. COLI” INFECTIONS OF THE GENITO‐URINARY TRACT

SUMMARY Fourteen cases of B, coli genito‐urinary infections were treated with Urolucosil. Ten were completely cured. The other four showed clinical improvement and at the time of discharge were symptom‐free; three had a persistence of the colipyuria, and one had a pyuria with no return of the B. coli to the urine. From the above results it would seem that Urolucosil is effective against B. coli urinary infections and it is non‐toxic even when given over a prolonged period. With the exception of Case 6 there would appear to be no evidence of drug resistance. Even in the event of a relapse, following maintenance dosage, increase to a normal therapeutic dosage appears to control the infection rapidly. A minimum maintenance dosage of one tablet three times a day is considered advisable, because an instance of recurrence of colipyuria during treatment by one tablet a day is recorded. One case was referred for operation and a most persistent colipyuria was controlled up to the time the operation was performed–this would seem to be a most useful indication for treatment with Urolucosil. The cases have been followed up for a lengthy period owing to their attendance for other reasons at a venereal diseases clinic. In only one case was a blood picture carried out, but that patient had received more treatment than any of the others and a satisfactory blood picture was obtained. This patient also had cultures of fæces, which apparently demonstrated that no major change in the intestinal flora resulted from Urolucosil treatment. All the cases were complicated either by a previous or present infection with venereal diseases, with the exception of one female case. The approved international non‐proprietary name of Urolucosil is sulphamethiazole.